Clinical review: Treatment of vitreoretinal lymphoma

Ocular Immunology and Inflammation

Volumn 17, Issue 5, 2009, Pages 299-306

  Péer, Jacob ^a   Hochberg, Fred H ^b   Foster, C Stephen ^c  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c MASSACHUSETTS EYE RESEARCH AND SURGERY INSTITUTION   (United States)

Author keywords

Biological therapy; Chemotherapy; Primary central nervous system lymphoma (PCNSL); Radiation therapy; Vitreoretinal lymphoma

Indexed keywords

ALEMTUZUMAB; ANTINEOPLASTIC AGENT; BUSULFAN; CHLORMETHINE; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DACLIZUMAB; DEXAMETHASONE; DEXAMETHASONE SODIUM PHOSPHATE; EFALIZUMAB; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; IFOSFAMIDE; IMMUNOTOXIN; IMMUNOTOXIN HA22; LOMUSTINE; METHOTREXATE; METHYLPREDNISOLONE; PROCARBAZINE; RITUXIMAB; THIOTEPA; TROFOSFAMIDE; UNCLASSIFIED DRUG; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; CANCER RADIOTHERAPY; CANCER REGRESSION; DRUG EFFECT; DRUG HALF LIFE; DRUG MEGADOSE; EYE CANCER; EYE DISEASE; EYE INFLAMMATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LYMPHOMA; NONHUMAN; RADIATION DOSE; RETINA MACULOPATHY; REVIEW; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VISUAL ACUITY; VITREORETINAL LYMPHOMA;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BIOLOGICAL THERAPY; EYE NEOPLASMS; HUMANS; LYMPHOMA; RETINAL NEOPLASMS; VITREOUS BODY;

EID: 70350157237     PISSN: 09273948     EISSN: 17445078     Source Type: Journal    
DOI: 10.3109/09273940903370755     Document Type: Review

References (59)

1. Coupland SE, Damato B. Understanding intraocular lymphomas. Clin Exp Ophthalmol. 2008;36:564-578.
2. Coupland SE, Heimann H, Bechrakis NE. Primary intraocular lymphoma: a review of the clinical, histopathological and molecular biological features. Graefes Arch Clin Exp Ophthalmol. 2004;242:901-913.
3. Nussenblatt RB, Chan CC, Wilson WH, et al. International Central Nervous System and Ocular Lymphoma Workshop: Recommendations for the Future. Ocul Immunol Inflamm. 2006;14:139-144.
4. Grimm SA, McCannel CA, Omuro AMO, et al. Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group Report. Neurology. 2008;71: 1355-1360.
5. Peterson K, Gordon KB, Heinemann MH, et al. The clinical spectrum of ocular lymphoma. Cancer. 1993;72:843-849.
6. Cassoux N, Merle-Beral H, Leblond V, et al. Ocular and central nervous system lymphoma: clinical features and diagnosis. Ocul Immunol Inflamm. 2000;8:243-250.
7. Hochberg FH, Miller DC. Primary central nervous system lymphoma. J Neurosurg. 1988;68:835-853.
8. Choi JY, Kafkala C, Foster CS. Primary intraocular lymphoma: a review. Semin Ophthalmol. 2006;21:125-133.
9. Enting RH, Demopoulos A, DeAngelis LM, et al. Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology 2004;63:901-903.
10. Grimm SA, Pulido JS, Jahnke K, et al. Primary intraocular lymphoma: an International Primary Central Nervous System Lymphoma Collaborative Group Report. Ann Oncol. 2007;18:1851-1855.
11. Ferreri AJM, Blay JY, Reni M, et al. Relevance of intraocular involvement in the management of primary central nervous system lymphomas. Ann Oncol. 2002;13:531-538.
12. Cooper EL, Riker JL. Malignant lymphoma of the uveal tract. Am J Ophthalmol. 1951;34:1153-1158.
13. Vogel MH, Font RL, Zimmerman LE, et al. Reticulum cell sarcoma of the retina and uvea. Report of six cases and review of the literature. Am J Ophthalmol. 1968;66: 205-215.
14. Margolis L, Fraser R, Lichter A, et al. The role of radiation therapy in the management of ocular reticulum cell sarcoma. Cancer. 1980;45:688-692.
15. Char DH, Margolis L, Newman AB. Ocular reticulum cell sarcoma. Am J Ophthalmol. 1981;91:480-483.
16. Char DH, Ljung BM, Deschênes J, et al. Intraocular lymphoma: immunological and cytological analysis. Br J Ophthalmol. 1988;72:905-911.
17. Char DH, Ljung BM, Miller T, et al. Primary intraocular lymphoma (ocular reticulum cell sarcoma) diagnosis and management. Ophthalmology. 1988;95:625-630.
18. Siegel MJ, Dalton J, Friedman AH, et al. Ten-year experience with primary ocular 'reticulum cell sarcoma' (large cell non-Hodgkin's lymphoma). Br J Ophthalmol. 1989;73: 342-1246
19. Hoffman PM, McKelvie P, Hall AJ, et al. Intraocular lymphoma: a series of 14 patients with clinicopathological features and treatment outcomes. Eye. 2003;17:513-521.
20. Hormigo A, Albreg L, Heinemann MH, et al. Ocular presentation of primary central nervous system lymphoma: diagnosis and treatment. Br J Hematol. 2004;126:202-208.
21. Isobe K, Ejima Y, Tokumaru S, et al. Treatment of primary intraocular lymphoma with radiation therapy: A multiinstitutional survey in Japan. Leuk Lymphoma. 2006;47: 1800-1805.
22. Berenbom A, Davila RM, Lin HS, et al. Treatment outcomes for primary intraocular lymphoma: implications for external beam radiotherapy. Eye. 2007;1198-1201.
23. Soussain C, Merle-Beral H, Reux I, et al. A single-center study of 11 patients with intraocular lymphoma treated with conventional chemotherapy followed by highdose chemotherapy and autologous bone marrow transplantation in 5 cases. Leuk Lymphoma. 1996;23: 339-345.
24. Sullivan SF, Dallow RL. Intraocular reticulum cell sarcoma: its dramatic response to systemic chemotherapy and its angiogenic potential. Ann Ophthalmol. 1977;9:401-406.
25. Baumann MA, Ritch PS, Harde KR, et al. Treatment of intraocular lymphoma with high-dose Ara-C. Cancer. 1986;57:1273-1275.
26. Strauchen JA, Dalton J, Friedman AH. Chemotherapy in the management of intraocular lymphoma. Cancer. 1989;63:1918-1921.
27. Valluri S, Moorthy RS, Khan A, et al. Combination treatment of intraocular lymphoma. Retina. 1995;15:125-129.
28. Batchelor TT, Kolak G, Ciordia R, et al. High-dose methotrexate for intraocular lymphoma. Clin Can Res. 2003; 9:711-715.
29. Henson JW, Yang J, Batchelor T. Intraocular methotrexate level after high-dose intravenous infusion. J Clin Oncol. 1999;17:1329.
30. Gudauskas G, Ostry A, Rootman J. Concentrations of tritiated methotrexate in ocular compartments, serum and urine after subconjunctival and intravenous injection. Can J Ophthalmol. 1980;15:179-182.
31. Eljarrat-Binstock E, Domb AJ, Orucov F, et al. Methotrexate delivery to the eye using transscleral hydrogel iontophoresis. Curr Eye Res. 2007;32:639-646.
32. Mason JO, Fischer DH. Intrathecal chemotherapy for recurrent central nervous system intraocular lymphoma. Ophthalmology. 2003;110:1241-1244.
33. de Smet MD, Stark-Vancs V, Kohler DR, et al. Intraocular levels of methotrexate after intravenous administration. Am J Ophthalmol. 1996;121:442-444.
34. Kim SK, Chan CC, Wallace DJ. Management of primary intraocular lymphoma. Curr Oncol Rep. 2005;7:74-79.
35. Jahnke K, Thiel F, Bechrakis NE, et al. Ifosfamide or trofosfamide in patients with intraocular lymphoma. J Neurooncol. 2009;93:213-217.
36. Sandor V, Stark-Vancs V, Pearson D, et al. Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma. J Clin Oncol. 1998;16:3000-3006.
37. Soussain C, Hoang-Xuan K, Taillandier L, et al. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire. J Clin Oncol. 2008;26: 2512-2516.
38. Ericson L, Karlberg B, Rosengren BHO. Trials of intravitreal injections of chemotherapeutic agents in rabbits. Acta Ophthalmol. 1964;42:721-726.
39. Fishburne BC, Wilson DJ, Rosenbaum JT, et al. Intravitreal methotrexate as an adjunctive treatment of intraocular lymphoma. Arch Ophthalmol. 1997;115:1152-1156.
40. de Smet MD, Vancs VS, Kohler D, et al. Intravitreal chemotherapy for the treatment of recurrent intraocular lymphoma. Br J Ophthalmol. 1999;83:448-451.
41. de Smet MD. Management of non-Hodgkin's intraocular lymphoma with intravitreal methotrexate. Bull Soc Belge Ophthalmol. 2001;279:91-95.
42. Velez G, Boldt HC, Whitcup SM, et al. Local methotrexate and dexamethasone phosphate for the treatment of recurrent primary intraocular lymphoma. Ophthalmic Surg Lasers. 2002;33:329-333
43. Velez G, Yuan P, Sung BC, et al. Pharmacokinetics and toxicity of intravitreal chemotherapy for primary intraocular lymphoma. Arch Ophthalmol. 2001;119: 1518-1524.
44. Smith JR, Rosenbaum JT, Wilson DJ, et al. Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement. Ophthalmology. 2002;109:1709-1716.
45. Frenkel S, Hendler K, Siegal T, et al. Intravitreal methotrexate for treating vitreoretinal lymphoma: Ten years of experience. Br J Ophthalmol. 2008; 92:383-388.
46. Angelov L, Doolittle ND, Kraemer DF, et al. Blood-brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: a multi-institutional experience. J Clin Oncol. 2009;27: 3503-3509.
47. Vicuna-Kojchen J, Frenkel S, Siegal T, et al. Maculo- pathy in patients with primary CNS lymphoma treated with chemotherapy in conjunction with blood-brain barrier disruption (BBBD). Br J Ophthalmol. 2008;92: 231-235.
48. Sou R, Ohguro N, Maeda T, et al. Treatment of primary intraocular lymphoma with intravitreal methotrexate. Jpn J Ophthalmol. 2008;52:167-174.
49. Sen HN, Chan CC. Intravitreal methotrexate resistance in a patient with primary intaocular lymphoma. Ocul Immunol Inflamm. 2008;16:29-33.
50. Kim H, Csaky KG, Chan CC, et al. The pharmacokinetics of rituximab following an intravitreal injection. Exp Eye Res. 2006;82:760-766.
51. Pulido JS, Bakri SJ, Valyi-Nagy T, et al. Rituximab penetrates full-thickness retina in contrast to tissue plasminogen activator control. Retina. 2007;1071-1073.
52. Kitzmann AS, Pulido JS, Mohney BG, et al. Intraocular use of rituximab. Eye. 2007;21:1524-1527.
53. Mineo JF, Scheffer A, Karkoutly C, et al. Using human CD20-transfected murine lymphomatous B cells to evaluate the efficacy of intravitreal and intracerebral rituximab injections in mice. Invest Ophthalmol Vis Sci. 2008;49:4738-4745.
54. Itty S, Olson JH, O'Connell DJ, et al. Treatment of primary intraocular lymphoma (PIOL) has involved systemic,intravitreal and intrathecal chemotherapy and/or radiotherapy. Retina. 2009;29:415-416.
55. Ohguro N, Hashida N, Tano Y. Effect of intravitreous rituximab injections in patients with ocular lesions associated with central nervous system lymphoma. Arch Ophthalmol. 2008;126:1002-1003.
56. Gregory MS, Koh S, Huang E, et al. A novel treatment for ocular tumors using membrane FasL vesicles to activate innate immunity and terminate immune privilege. Invest Ophthalmol Vis Sci. 2005;46:2495-2502.
57. Li Z, Mahesh SP, Shen DF, et al. Eradication of tumor colonization and invasion by a B cell-specific immunotoxin in a murine model for human primary intraocular lymphoma. Cancer Res. 2006;66:10586-10593.
58. Pastan I, Beers R, Bera TK. Recombinant immunotoxins in the treatment of cancer. Methods Mol Biol. 2004;248:503-518.
59. Rodrigues EB, Farah ME, Maia M, et al. Therapeutic monoclonal antibodies in ophthalmology. Prog Retin Eye Res. 2009;28:117-144.